Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis

Robert J. Hoyer, Nelson Leung, Thomas E. Witzig, Martha Q. Lacy

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Refractory pleural effusions present a challenging management problem and are associated with a poor prognosis in patients with primary systemic amyloidosis (AL). We report a series of four patients with AL who presented with bilateral pleural effusions that were refractory to diuretic therapy. After treatment with bevacizumab, an antivascular endothelial growth factor (VEGF) antibody, three of the four patients had improvement in their pleural effusions, peripheral edema, and functional status. Additional studies are needed to further define the role of bevacizumab in the management of this group of patients.

Original languageEnglish (US)
Pages (from-to)409-413
Number of pages5
JournalAmerican journal of hematology
Volume82
Issue number5
DOIs
StatePublished - May 1 2007

Keywords

  • Amyloidosis
  • Bevacizumab
  • Pleural effusion
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis'. Together they form a unique fingerprint.

  • Cite this